Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEPHEN MICHAEL SCHLEICHER

Allopathic & Osteopathic Physicians Dermatology

NPI
1861487449
CMS profile
39262
Location
SUGARLOAF, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,644.53

133 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,464.55 131
Education $179.98 2

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–133 of 133 matching records. This page contains 33 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEPHEN MICHAEL SCHLEICHER

NPI 1861487449 · CMS profile ID 39262

Allopathic & Osteopathic Physicians / Dermatology

SUGARLOAF, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–133 of 133 matching records. This page contains 33 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1861487449?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEPHEN MICHAEL SCHLEICHER, NPI 1861487449, CMS profile ID 39262. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–133 of 133 matching records. This page contains 33 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861487449?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). STEPHEN MICHAEL SCHLEICHER, NPI 1861487449, CMS profile ID 39262. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–133 of 133 matching records. This page contains 33 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861487449?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
STEPHEN MICHAEL SCHLEICHER, NPI 1861487449, CMS profile ID 39262, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–133 of 133 matching records. This page contains 33 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1861487449?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

133 matching records · $2,644.53 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 133 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–133 of 133.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $13.3104/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835980069 CMS
UCB, Inc. $8.6604/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807337263 CMS
AbbVie Inc. $12.0504/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795985907 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $14.2804/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851931897 CMS
Janssen Biotech, Inc. $14.9304/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788761015 CMS
Janssen Biotech, Inc. $2.6104/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788761053 CMS
Janssen Biotech, Inc. $79.9903/29/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788761013 CMS
UCB, Inc. $22.8603/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807299629 CMS
Janssen Biotech, Inc. $5.4003/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788761051 CMS
GENZYME CORPORATION $14.9303/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843403459 CMS
Regeneron Healthcare Solutions, Inc. $13.7903/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809621837 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $67.6303/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851931891 CMS
GENZYME CORPORATION $11.1103/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843403455 CMS
UCB, Inc. $19.8303/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807331289 CMS
UCB, Inc. $5.0603/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807316809 CMS
Lilly USA, LLC $14.3003/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818701877 CMS
UCB, Inc. $21.7102/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807318555 CMS
UCB, Inc. $1.3602/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807301839 CMS
Janssen Biotech, Inc. $10.9202/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788761045 CMS
Janssen Biotech, Inc. $3.5702/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788761047 CMS
UCB, Inc. $13.5002/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807305587 CMS
Janssen Biotech, Inc. $9.2202/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788761049 CMS
Janssen Biotech, Inc. $2.4902/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788761043 CMS
PFIZER INC. $15.8902/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832746885 CMS
UCB, Inc. $1.8202/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807311381 CMS
AbbVie Inc. $21.8401/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795985905 CMS
Galderma Laboratories, L.P. $13.5601/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855301237 CMS
ORGANOGENESIS INC. $14.4501/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835462495 CMS
UCB, Inc. $21.6501/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807309735 CMS
AbbVie Inc. $16.6701/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795985903 CMS
Regeneron Healthcare Solutions, Inc. $15.3401/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809621835 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $87.7001/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851931893 CMS
GENZYME CORPORATION $15.0901/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843403433 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,307.47 115
PY2020 $2,371.77 52
PY2021 $2,644.53 133
PY2022 $4,662.52 179
PY2023 $4,279.22 182
PY2024 $3,407.29 155
PY2025 $5,459.01 91

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $988,653.24 445
PY2024 Recipient $350.79 2
PY2024 Principal investigator $578,899.60 232
PY2023 Recipient $44,993.44 3
PY2023 Principal investigator $246,322.57 84
PY2022 Recipient $44,091.91 5
PY2022 Principal investigator $109,384.41 13
PY2021 Recipient $403,393.25 6
PY2021 Principal investigator $225,295.49 139
PY2020 Recipient $177,244.24 7
PY2020 Principal investigator $116,795.58 23
PY2019 Recipient $79,567.33 44
PY2019 Principal investigator $51,766.90 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

445 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Hoffmann-La Roche Limited $2,194.00 12/22/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578988
Principal investigator 1 Hoffmann-La Roche Limited $1,800.00 12/22/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211579009
Principal investigator 1 Hoffmann-La Roche Limited $4,388.00 12/22/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211579058
Principal investigator 1 Incyte Corporation $10.00 12/19/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508328
Principal investigator 1 Incyte Corporation $93.00 12/19/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508341
Principal investigator 1 Incyte Corporation $231.00 12/19/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508345
Principal investigator 1 Incyte Corporation $1,500.00 12/19/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508349
Principal investigator 1 Incyte Corporation $55.00 12/19/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508407
Principal investigator 1 Incyte Corporation $1,000.00 12/19/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508423
Principal investigator 1 SANOFI US SERVICES INC. $141.36 12/17/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226158490
Principal investigator 1 SANOFI US SERVICES INC. $1,218.30 12/17/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226158494
Principal investigator 1 SANOFI US SERVICES INC. $1,120.65 12/17/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226158497
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 12/17/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226158517
Principal investigator 1 Hoffmann-La Roche Limited $1,800.00 12/11/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578991
Principal investigator 1 Incyte Corporation $693.00 12/08/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508383
Principal investigator 1 Incyte Corporation $100.00 12/08/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508392
Principal investigator 1 Incyte Corporation $100.00 12/08/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508396
Principal investigator 1 Incyte Corporation $30.00 12/08/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508400
Principal investigator 1 Incyte Corporation $372.00 12/08/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508404
Principal investigator 1 Incyte Corporation $220.00 12/08/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508411
Principal investigator 1 Incyte Corporation $90.00 12/08/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508430
Principal investigator 1 SANOFI US SERVICES INC. $436.77 12/03/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226158506
Principal investigator 1 SANOFI US SERVICES INC. $528.98 12/03/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226158510
Principal investigator 1 SANOFI US SERVICES INC. $85.00 12/02/2025 Non-covered Recipient Entity
Best Skin Research Llc
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226099791
Principal investigator 1 SANOFI US SERVICES INC. $85.00 12/02/2025 Non-covered Recipient Entity
Best Skin Research Llc
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226099804
Principal investigator 1 SANOFI US SERVICES INC. $50.00 12/02/2025 Non-covered Recipient Entity
Best Skin Research Llc
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226099810
Principal investigator 1 Hoffmann-La Roche Limited $1,534.00 12/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578980
Principal investigator 1 Hoffmann-La Roche Limited $2,194.00 12/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578999
Principal investigator 1 Hoffmann-La Roche Limited $1,580.00 12/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211579013
Principal investigator 1 Hoffmann-La Roche Limited $1,728.00 12/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211579017
Principal investigator 1 Hoffmann-La Roche Limited $1,728.00 12/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211579026
Principal investigator 1 Hoffmann-La Roche Limited $1,534.00 12/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211579037
Principal investigator 1 Hoffmann-La Roche Limited $1,825.00 12/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211579042
Principal investigator 1 Hoffmann-La Roche Limited $1,534.00 12/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211579046
Principal investigator 1 Hoffmann-La Roche Limited $1,534.00 12/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211579055
Principal investigator 1 Incyte Corporation $60.00 12/01/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508354
Principal investigator 1 Incyte Corporation $186.00 12/01/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508370
Principal investigator 1 Incyte Corporation $110.00 12/01/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508374
Principal investigator 1 Incyte Corporation $20.00 12/01/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508379
Principal investigator 1 Incyte Corporation $30.00 12/01/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508419
Principal investigator 1 Incyte Corporation $462.00 12/01/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508427
Principal investigator 1 SANOFI US SERVICES INC. $2,031.00 12/01/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226158502
Principal investigator 1 Incyte Corporation $462.00 11/24/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508332
Principal investigator 1 Incyte Corporation $186.00 11/24/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508336
Principal investigator 1 Incyte Corporation $184.00 11/24/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508362
Principal investigator 1 Incyte Corporation $30.00 11/24/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508366
Principal investigator 1 Incyte Corporation $110.00 11/24/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508388
Principal investigator 1 Incyte Corporation $20.00 11/24/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508415
Principal investigator 1 SANOFI US SERVICES INC. $6,602.00 11/24/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226099798
Principal investigator 1 SANOFI US SERVICES INC. $1,992.50 11/14/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226158514
Principal investigator 1 SANOFI US SERVICES INC. $5,838.75 11/14/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226158522
Principal investigator 1 Amgen Inc. $15,337.48 11/06/2025 Non-covered Recipient Entity
DANA M MAUCH, CRA, DBA DMMRESEARCH
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) No dispute reported 06/30/2026 1246640623
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $11,725.00 11/04/2025 Non-covered Recipient Entity
Best Skin Research, Llc
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235998674
Principal investigator 1 Hoffmann-La Roche Limited $1,534.00 11/03/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578983
Principal investigator 1 Hoffmann-La Roche Limited $1,728.00 11/03/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578995
Principal investigator 1 Hoffmann-La Roche Limited $1,534.00 11/03/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211579002
Principal investigator 1 Hoffmann-La Roche Limited $1,681.00 11/03/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211579006
Principal investigator 1 Hoffmann-La Roche Limited $1,534.00 11/03/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211579021
Principal investigator 1 Hoffmann-La Roche Limited $785.00 11/03/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211579029
Principal investigator 1 Hoffmann-La Roche Limited $1,534.00 11/03/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211579033
Principal investigator 1 Hoffmann-La Roche Limited $1,728.00 11/03/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211579051
Principal investigator 1 Hoffmann-La Roche Limited $1,728.00 11/03/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211579063
Principal investigator 1 Hoffmann-La Roche Limited $1,345.00 11/03/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211579067
Principal investigator 1 Incyte Corporation $1,129.50 10/24/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508358
Principal investigator 1 SANOFI US SERVICES INC. $1,350.00 10/14/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226099647
Principal investigator 1 Hoffmann-La Roche Limited $246.00 10/13/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578961
Principal investigator 1 SANOFI US SERVICES INC. $9,010.00 10/06/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226099642
Principal investigator 1 Hoffmann-La Roche Limited $1,825.00 10/02/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578941
Principal investigator 1 Hoffmann-La Roche Limited $1,728.00 10/02/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578945
Principal investigator 1 Hoffmann-La Roche Limited $1,534.00 10/02/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578949
Principal investigator 1 Hoffmann-La Roche Limited $1,534.00 10/02/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578953
Principal investigator 1 Hoffmann-La Roche Limited $1,728.00 10/02/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578956
Principal investigator 1 Hoffmann-La Roche Limited $1,728.00 10/02/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578965
Principal investigator 1 Hoffmann-La Roche Limited $1,534.00 10/02/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578968
Principal investigator 1 Hoffmann-La Roche Limited $1,534.00 10/02/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578971
Principal investigator 1 Hoffmann-La Roche Limited $1,534.00 10/02/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578975
Principal investigator 1 SANOFI US SERVICES INC. $5,071.25 09/24/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226158460
Principal investigator 1 SANOFI US SERVICES INC. $6,637.50 09/24/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226158464
Principal investigator 1 SANOFI US SERVICES INC. $150.00 09/24/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226158484
Principal investigator 1 SANOFI US SERVICES INC. $150.00 09/24/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226158487
Principal investigator 1 SANOFI US SERVICES INC. $360.00 09/22/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226099634
Principal investigator 1 Hoffmann-La Roche Limited $325.00 09/12/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578729
Principal investigator 1 Hoffmann-La Roche Limited $585.00 09/12/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578737
Principal investigator 1 Hoffmann-La Roche Limited $3,352.00 09/12/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578739
Principal investigator 1 Hoffmann-La Roche Limited $585.00 09/12/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578743
Principal investigator 1 Hoffmann-La Roche Limited $164.00 09/12/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578769
Principal investigator 1 Hoffmann-La Roche Limited $585.00 09/12/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578780
Principal investigator 1 Hoffmann-La Roche Limited $585.00 09/12/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578784
Principal investigator 1 Hoffmann-La Roche Limited $455.00 09/12/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578804
Principal investigator 1 Hoffmann-La Roche Limited $585.00 09/12/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578834
Principal investigator 1 Hoffmann-La Roche Limited $33.00 09/12/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578838
Principal investigator 1 Hoffmann-La Roche Limited $325.00 09/12/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578846
Principal investigator 1 Hoffmann-La Roche Limited $260.00 09/12/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578862
Principal investigator 1 Hoffmann-La Roche Limited $455.00 09/12/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578870
Principal investigator 1 Hoffmann-La Roche Limited $585.00 09/12/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578877
Principal investigator 1 Hoffmann-La Roche Limited $55.00 09/12/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578882
Principal investigator 1 Hoffmann-La Roche Limited $325.00 09/12/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578886
Principal investigator 1 Hoffmann-La Roche Limited $64.00 09/12/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578898
Principal investigator 1 Hoffmann-La Roche Limited $676.00 09/12/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578907
Principal investigator 1 Hoffmann-La Roche Limited $650.00 09/12/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578911
Principal investigator 1 Hoffmann-La Roche Limited $585.00 09/12/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578928
Principal investigator 1 SANOFI US SERVICES INC. $4,048.20 09/08/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226099621
Principal investigator 1 Incyte Corporation $186.00 09/05/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508240
Principal investigator 1 Incyte Corporation $184.00 09/05/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508244
Principal investigator 1 Incyte Corporation $110.00 09/05/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508247
Principal investigator 1 Incyte Corporation $60.00 09/05/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508251
Principal investigator 1 Incyte Corporation $20.00 09/05/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508259
Principal investigator 1 Incyte Corporation $693.00 09/05/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508263
Principal investigator 1 Incyte Corporation $55.00 09/05/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508267
Principal investigator 1 Incyte Corporation $231.00 09/05/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508271
Principal investigator 1 Incyte Corporation $30.00 09/05/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508279
Principal investigator 1 Incyte Corporation $10.00 09/05/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508283
Principal investigator 1 Incyte Corporation $93.00 09/05/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508296
Principal investigator 1 Hoffmann-La Roche Limited $1,728.00 09/04/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578765
Principal investigator 1 Hoffmann-La Roche Limited $1,580.00 09/04/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578773
Principal investigator 1 Hoffmann-La Roche Limited $785.00 09/04/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578788
Principal investigator 1 Hoffmann-La Roche Limited $1,580.00 09/04/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578792
Principal investigator 1 Hoffmann-La Roche Limited $1,534.00 09/04/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578812
Principal investigator 1 Hoffmann-La Roche Limited $1,728.00 09/04/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578830
Principal investigator 1 Hoffmann-La Roche Limited $2,194.00 09/04/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578854
Principal investigator 1 Hoffmann-La Roche Limited $1,580.00 09/04/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578889
Principal investigator 1 Hoffmann-La Roche Limited $1,534.00 09/04/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578915
Principal investigator 1 Incyte Corporation $50.00 09/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508304
Principal investigator 1 SANOFI US SERVICES INC. $6,932.00 09/03/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226099615
Principal investigator 1 Incyte Corporation $11.45 09/02/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527893
Principal investigator 1 SANOFI US SERVICES INC. $480.00 08/25/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226099626
Principal investigator 1 Hoffmann-La Roche Limited $338.00 08/13/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578822
Principal investigator 1 Hoffmann-La Roche Limited $86.00 08/13/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578920
Principal investigator 1 Hoffmann-La Roche Limited $1,676.00 08/13/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578933
Principal investigator 1 SANOFI US SERVICES INC. $19,488.75 08/13/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226158456
Principal investigator 1 SANOFI US SERVICES INC. $3,654.90 08/11/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226099191
Principal investigator 1 SANOFI US SERVICES INC. $5,035.10 08/11/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226099197
Principal investigator 1 SANOFI US SERVICES INC. $436.25 08/08/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226158472
Principal investigator 1 SANOFI US SERVICES INC. $303.75 08/08/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226158476
Principal investigator 1 SANOFI US SERVICES INC. $557.50 08/08/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226158480
Principal investigator 1 Hoffmann-La Roche Limited $676.00 08/06/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578752
Principal investigator 1 Hoffmann-La Roche Limited $123.00 08/06/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578858
Principal investigator 1 Hoffmann-La Roche Limited $3,352.00 08/06/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578894
Principal investigator 1 SANOFI US SERVICES INC. $6,272.00 08/04/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226099177
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,200.00 08/01/2025 Non-covered Recipient Entity
Vial Health Technologies Inc
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1235991963
Principal investigator 1 Hoffmann-La Roche Limited $1,580.00 08/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578733
Principal investigator 1 Hoffmann-La Roche Limited $1,395.00 08/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578748
Principal investigator 1 Hoffmann-La Roche Limited $1,681.00 08/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578756
Principal investigator 1 Hoffmann-La Roche Limited $1,345.00 08/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578761
Principal investigator 1 Hoffmann-La Roche Limited $1,395.00 08/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578776
Principal investigator 1 Hoffmann-La Roche Limited $1,825.00 08/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578795
Principal investigator 1 Hoffmann-La Roche Limited $1,681.00 08/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578799
Principal investigator 1 Hoffmann-La Roche Limited $1,825.00 08/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578808
Principal investigator 1 Hoffmann-La Roche Limited $1,681.00 08/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578816
Principal investigator 1 Hoffmann-La Roche Limited $1,681.00 08/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578827
Principal investigator 1 Hoffmann-La Roche Limited $1,580.00 08/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578842
Principal investigator 1 Hoffmann-La Roche Limited $1,534.00 08/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578850
Principal investigator 1 Hoffmann-La Roche Limited $2,194.00 08/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578866
Principal investigator 1 Hoffmann-La Roche Limited $2,194.00 08/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578903
Principal investigator 1 Hoffmann-La Roche Limited $1,395.00 08/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578925
Principal investigator 1 Hoffmann-La Roche Limited $1,534.00 08/01/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578937
Principal investigator 1 SANOFI US SERVICES INC. $300.00 07/28/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226099183
Principal investigator 1 SANOFI US SERVICES INC. $1,370.00 07/21/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226099165
Principal investigator 1 Incyte Corporation $100.00 07/18/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508275
Principal investigator 1 Incyte Corporation $177.00 07/18/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508287
Principal investigator 1 Incyte Corporation $41.00 07/18/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508291
Principal investigator 1 Incyte Corporation $85.00 07/18/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508300
Principal investigator 1 Incyte Corporation $101.00 07/18/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508316
Principal investigator 1 Incyte Corporation $539.00 07/18/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508321
Principal investigator 1 Incyte Corporation $1,463.90 07/16/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508308
Principal investigator 1 Incyte Corporation $1,314.00 07/16/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508312
Principal investigator 1 Incyte Corporation $1,255.00 07/16/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508325
Principal investigator 1 SANOFI US SERVICES INC. $1,800.00 07/09/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226158468
Principal investigator 1 Incyte Corporation $525.00 07/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508212
Principal investigator 1 Incyte Corporation $449.40 07/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508225
Principal investigator 1 Incyte Corporation $562.00 07/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508234
Principal investigator 1 Incyte Corporation $443.52 07/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508255
Principal investigator 1 SANOFI US SERVICES INC. $12,080.00 07/07/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226099158
Principal investigator 1 Incyte Corporation $539.00 07/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508205
Principal investigator 1 Incyte Corporation $85.00 07/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508208
Principal investigator 1 Incyte Corporation $177.00 07/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508216
Principal investigator 1 Incyte Corporation $123.00 07/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508221
Principal investigator 1 Incyte Corporation $50.00 07/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508230
Principal investigator 1 SANOFI US SERVICES INC. $180.00 07/02/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226099137
Principal investigator 1 SANOFI US SERVICES INC. $3,212.40 07/02/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226099145
Principal investigator 1 SANOFI US SERVICES INC. $12,673.75 07/02/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226158452
Principal investigator 1 Incyte Corporation $22.90 07/01/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240527890
Principal investigator 1 Incyte Corporation $1,500.00 06/25/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240508083
Principal investigator 1 Incyte Corporation $1,000.00 06/25/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240508101
Principal investigator 1 Incyte Corporation $1,258.00 06/20/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508104
Principal investigator 1 Incyte Corporation $1,460.00 06/20/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508115
Principal investigator 1 Genentech, Inc. $2,194.00 06/18/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578618
Principal investigator 1 Genentech, Inc. $1,825.00 06/18/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578622
Principal investigator 1 Genentech, Inc. $1,534.00 06/18/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578630
Principal investigator 1 Genentech, Inc. $2,194.00 06/18/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578634
Principal investigator 1 Genentech, Inc. $1,395.00 06/18/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578638
Principal investigator 1 Genentech, Inc. $1,681.00 06/18/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578642
Principal investigator 1 Genentech, Inc. $1,534.00 06/18/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578645
Principal investigator 1 Genentech, Inc. $2,194.00 06/18/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578649
Principal investigator 1 Genentech, Inc. $1,825.00 06/18/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578653
Principal investigator 1 Genentech, Inc. $1,825.00 06/18/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578661
Principal investigator 1 Genentech, Inc. $1,825.00 06/18/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578665
Principal investigator 1 Genentech, Inc. $2,194.00 06/18/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578669
Principal investigator 1 Genentech, Inc. $1,395.00 06/18/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578674
Principal investigator 1 Genentech, Inc. $1,395.00 06/18/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578678
Principal investigator 1 Genentech, Inc. $1,534.00 06/18/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578683
Principal investigator 1 Genentech, Inc. $1,681.00 06/18/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578687
Principal investigator 1 Genentech, Inc. $1,395.00 06/18/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578696
Principal investigator 1 Genentech, Inc. $1,534.00 06/18/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578701
Principal investigator 1 Genentech, Inc. $1,825.00 06/18/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578705
Principal investigator 1 Genentech, Inc. $2,194.00 06/18/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578713
Principal investigator 1 Genentech, Inc. $1,534.00 06/18/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578717
Principal investigator 1 Genentech, Inc. $1,681.00 06/18/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578720
Principal investigator 1 Incyte Corporation $1,195.00 06/18/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508121
Principal investigator 1 SANOFI US SERVICES INC. $12,295.00 06/16/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226099113
Principal investigator 1 SANOFI US SERVICES INC. $35.00 06/16/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226099119
Principal investigator 1 Incyte Corporation $680.50 06/13/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240508163
Principal investigator 1 SANOFI US SERVICES INC. $12,487.50 06/11/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226158447
Principal investigator 1 SANOFI US SERVICES INC. $3,007.20 06/09/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226099101
Principal investigator 1 SANOFI US SERVICES INC. $840.00 06/09/2025 Non-covered Recipient Entity
Best Skin Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226099108
Principal investigator 1 Incyte Corporation $99.12 06/03/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527829
Principal investigator 1 Incyte Corporation $77.75 06/03/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240527840
Principal investigator 1 Incyte Corporation $19.20 06/03/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527852
Principal investigator 1 Incyte Corporation $30.52 06/03/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527855
Principal investigator 1 Incyte Corporation $7.84 06/03/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527861
Principal investigator 1 Incyte Corporation $231.40 06/03/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527865
Principal investigator 1 Incyte Corporation $30.52 06/03/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527869
Principal investigator 1 Incyte Corporation $30.52 06/03/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527873
Principal investigator 1 Incyte Corporation $30.52 06/03/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527877
Principal investigator 1 SANOFI US SERVICES INC. $415.00 05/27/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226099088
Principal investigator 1 SANOFI US SERVICES INC. $1,570.00 05/27/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226099094
Principal investigator 1 Genentech, Inc. $123.00 05/23/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578626
Principal investigator 1 Genentech, Inc. $838.00 05/23/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578657
Principal investigator 1 Genentech, Inc. $169.00 05/23/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578709
Principal investigator 1 Incyte Corporation $30.00 05/19/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240508001
Principal investigator 1 Incyte Corporation $94.00 05/19/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240508005
Principal investigator 1 Incyte Corporation $20.00 05/19/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240508019
Principal investigator 1 Incyte Corporation $59.00 05/19/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240508125
Principal investigator 1 Incyte Corporation $80.00 05/19/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240508173
Principal investigator 1 SANOFI US SERVICES INC. $8,579.00 05/19/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226099079
Principal investigator 1 Incyte Corporation $954.10 05/14/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507997
Principal investigator 1 Incyte Corporation $100.00 05/14/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240508009
Principal investigator 1 Incyte Corporation $1,479.00 05/14/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508013
Principal investigator 1 Incyte Corporation $1,460.00 05/14/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508016
Principal investigator 1 Incyte Corporation $188.00 05/14/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240508037
Principal investigator 1 Incyte Corporation $118.00 05/14/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240508108
Principal investigator 1 Incyte Corporation $1,560.00 05/14/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508182
Principal investigator 1 Incyte Corporation $898.90 05/12/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508025
Principal investigator 1 Incyte Corporation $1,766.00 05/12/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508045
Principal investigator 1 SANOFI US SERVICES INC. $12,300.00 05/12/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226099072
Principal investigator 1 Genentech, Inc. $7,793.00 05/05/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578692
Principal investigator 1 Genentech, Inc. $3,500.00 05/05/2025 Non-covered Recipient Entity
Best Skin Research
VELARITE No dispute reported 06/30/2026 1211578724
Principal investigator 1 SANOFI US SERVICES INC. $2,932.50 05/05/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226099067
Principal investigator 1 Incyte Corporation $30.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507970
Principal investigator 1 Incyte Corporation $40.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507979
Principal investigator 1 Incyte Corporation $50.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507994
Principal investigator 1 Incyte Corporation $164.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508022
Principal investigator 1 Incyte Corporation $123.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508030
Principal investigator 1 Incyte Corporation $85.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508033
Principal investigator 1 Incyte Corporation $41.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508040
Principal investigator 1 Incyte Corporation $101.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508049
Principal investigator 1 Incyte Corporation $1,155.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508053
Principal investigator 1 Incyte Corporation $231.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508057
Principal investigator 1 Incyte Corporation $100.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508063
Principal investigator 1 Incyte Corporation $120.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508067
Principal investigator 1 Incyte Corporation $123.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508071
Principal investigator 1 Incyte Corporation $110.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508075
Principal investigator 1 Incyte Corporation $100.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508079
Principal investigator 1 Incyte Corporation $184.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508087
Principal investigator 1 Incyte Corporation $184.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508092
Principal investigator 1 Incyte Corporation $924.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508096
Principal investigator 1 Incyte Corporation $275.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508112
Principal investigator 1 Incyte Corporation $94.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508129
Principal investigator 1 Incyte Corporation $110.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508142
Principal investigator 1 Incyte Corporation $186.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508146
Principal investigator 1 Incyte Corporation $162.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508150
Principal investigator 1 Incyte Corporation $465.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508154
Principal investigator 1 Incyte Corporation $465.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508159
Principal investigator 1 Incyte Corporation $100.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508178
Principal investigator 1 Incyte Corporation $275.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240508193
Principal investigator 1 Incyte Corporation $50.00 05/02/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508200
Principal investigator 1 SANOFI US SERVICES INC. $4,750.00 04/25/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226158440
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 04/25/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226158444
Principal investigator 1 Amgen Inc. $59,563.35 04/24/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH LLC
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246639607
Principal investigator 1 Incyte Corporation $1,640.00 04/23/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240507928
Principal investigator 1 Incyte Corporation $2,590.00 04/23/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240508197
Principal investigator 1 Eli Lilly and Company $5,750.00 04/21/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH LLC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, 52 WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN THE TREATMENT OF ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187878139
Principal investigator 1 Eli Lilly and Company $3,000.00 04/21/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH LLC
A STUDY OF LY3454738 IN THE TREATMENT OF ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187881248
Principal investigator 1 SANOFI US SERVICES INC. $8,383.00 04/21/2025 Non-covered Recipient Entity
Best Skin Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226099126
Principal investigator 1 Incyte Corporation $1,479.00 04/16/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507899
Principal investigator 1 Incyte Corporation $1,639.00 04/16/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507916
Principal investigator 1 Incyte Corporation $1,019.30 04/16/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507920
Principal investigator 1 Incyte Corporation $996.50 04/14/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507924
Principal investigator 1 Incyte Corporation $1,195.00 04/14/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507963
Principal investigator 1 Incyte Corporation $1,673.00 04/11/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507903
Principal investigator 1 Incyte Corporation $1,015.90 04/11/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507941
Principal investigator 1 Incyte Corporation $1,479.00 04/11/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508189
Principal investigator 1 CSL Behring $8,000.00 04/09/2025 Non-covered Recipient Entity
Best Skin Research
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects No dispute reported 06/30/2026 1252669558
Principal investigator 1 Incyte Corporation $539.00 04/09/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507907
Principal investigator 1 Incyte Corporation $101.00 04/09/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507912
Principal investigator 1 Incyte Corporation $85.00 04/09/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507932
Principal investigator 1 Incyte Corporation $205.00 04/09/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507936
Principal investigator 1 Incyte Corporation $255.00 04/09/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507945
Principal investigator 1 Incyte Corporation $323.00 04/09/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507951
Principal investigator 1 Incyte Corporation $101.00 04/09/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507954
Principal investigator 1 Incyte Corporation $82.00 04/09/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507959
Principal investigator 1 Incyte Corporation $164.00 04/09/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507986
Principal investigator 1 Incyte Corporation $59.00 04/09/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508134
Principal investigator 1 Incyte Corporation $59.00 04/09/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508184
Principal investigator 1 Eli Lilly and Company $2,700.00 04/08/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH LLC
A STUDY OF LY3972406 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 1187874849
Principal investigator 1 Incyte Corporation $202.00 04/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507967
Principal investigator 1 Incyte Corporation $164.00 04/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507974
Principal investigator 1 Incyte Corporation $646.00 04/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507982
Principal investigator 1 Incyte Corporation $85.00 04/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507990
Principal investigator 1 Incyte Corporation $118.00 04/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508138
Principal investigator 1 Incyte Corporation $1,250.00 04/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240508167
Principal investigator 1 Incyte Corporation $77.75 04/02/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240527833
Principal investigator 1 Incyte Corporation $119.04 04/02/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527836
Principal investigator 1 Incyte Corporation $297.36 04/02/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527844
Principal investigator 1 Incyte Corporation $244.92 04/02/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240527847
Principal investigator 1 Incyte Corporation $244.92 04/02/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240527881
Principal investigator 1 Incyte Corporation $244.92 04/02/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240527885
Principal investigator 1 SANOFI US SERVICES INC. $965.00 04/02/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226098909
Principal investigator 1 SANOFI US SERVICES INC. $4,224.60 04/02/2025 Non-covered Recipient Entity
Best Skin Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226098927
Principal investigator 1 SANOFI US SERVICES INC. $910.00 04/02/2025 Non-covered Recipient Entity
Best Skin Research Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226098932
Principal investigator 1 SANOFI US SERVICES INC. $8,556.00 04/02/2025 Non-covered Recipient Entity
Best Skin Research Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226098939
Principal investigator 1 SANOFI US SERVICES INC. $7,533.30 04/02/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226098962
Principal investigator 1 SANOFI US SERVICES INC. $2,500.00 03/24/2025 Non-covered Recipient Entity
Best Skin Research Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226098868
Principal investigator 1 SANOFI US SERVICES INC. $300.00 03/24/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226098874
Principal investigator 1 SANOFI US SERVICES INC. $2,500.00 03/24/2025 Non-covered Recipient Entity
Best Skin Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226098885
Principal investigator 1 SANOFI US SERVICES INC. $8,028.00 03/24/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226098897
Principal investigator 1 Incyte Corporation $1,331.10 03/19/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507727
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 03/17/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226098879
Principal investigator 1 Incyte Corporation $30.00 03/10/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507655
Principal investigator 1 Incyte Corporation $372.00 03/10/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507706
Principal investigator 1 Incyte Corporation $184.00 03/10/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507710
Principal investigator 1 Incyte Corporation $171.00 03/10/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507714
Principal investigator 1 Incyte Corporation $123.00 03/10/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507721
Principal investigator 1 Incyte Corporation $924.00 03/10/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507731
Principal investigator 1 Incyte Corporation $397.00 03/10/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507738
Principal investigator 1 Incyte Corporation $279.00 03/10/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507743
Principal investigator 1 Incyte Corporation $101.00 03/10/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507747
Principal investigator 1 Incyte Corporation $200.00 03/10/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507758
Principal investigator 1 Incyte Corporation $123.00 03/10/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507762
Principal investigator 1 Incyte Corporation $220.00 03/10/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507834
Principal investigator 1 Incyte Corporation $1,800.00 03/10/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507861
Principal investigator 1 Incyte Corporation $165.00 03/10/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507864
Principal investigator 1 Incyte Corporation $90.00 03/10/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507872
Principal investigator 1 SANOFI US SERVICES INC. $1,290.00 03/10/2025 Non-covered Recipient Entity
Best Skin Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226099028
Principal investigator 1 SANOFI US SERVICES INC. $1,997.82 03/10/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226099035
Principal investigator 1 Incyte Corporation $1,528.00 03/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507735
Principal investigator 1 Incyte Corporation $1,445.00 03/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507751
Principal investigator 1 Incyte Corporation $1,445.00 03/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507755
Principal investigator 1 Incyte Corporation $1,885.00 03/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507767
Principal investigator 1 Incyte Corporation $1,326.00 03/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507771
Principal investigator 1 Incyte Corporation $1,326.00 03/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507776
Principal investigator 1 Incyte Corporation $1,528.00 03/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507780
Principal investigator 1 Incyte Corporation $1,255.00 03/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507784
Principal investigator 1 Incyte Corporation $1,445.00 03/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507789
Principal investigator 1 Incyte Corporation $1,195.00 03/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507793
Principal investigator 1 Incyte Corporation $1,195.00 03/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507797
Principal investigator 1 Incyte Corporation $1,885.00 03/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507802
Principal investigator 1 Incyte Corporation $1,326.00 03/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507807
Principal investigator 1 Incyte Corporation $1,240.00 03/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507810
Principal investigator 1 Incyte Corporation $1,240.00 03/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507817
Principal investigator 1 Incyte Corporation $1,766.00 03/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507821
Principal investigator 1 Incyte Corporation $1,935.00 03/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507825
Principal investigator 1 Incyte Corporation $1,935.00 03/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507829
Principal investigator 1 Incyte Corporation $606.90 03/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507842
Principal investigator 1 Incyte Corporation $1,314.00 03/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507846
Principal investigator 1 Incyte Corporation $1,195.00 03/07/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240507896
Principal investigator 1 SANOFI US SERVICES INC. $1,070.00 03/04/2025 Non-covered Recipient Entity
Best Skin Research Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226098967
Principal investigator 1 SANOFI US SERVICES INC. $460.00 03/04/2025 Non-covered Recipient Entity
Best Skin Research Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226098976
Principal investigator 1 SANOFI US SERVICES INC. $19,860.00 03/04/2025 Non-covered Recipient Entity
Best Skin Research Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226098982
Principal investigator 1 SANOFI US SERVICES INC. $4,414.00 03/04/2025 Non-covered Recipient Entity
Best Skin Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226098988
Principal investigator 1 SANOFI US SERVICES INC. $1,365.00 03/04/2025 Non-covered Recipient Entity
Best Skin Research Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226098996
Principal investigator 1 SANOFI US SERVICES INC. $1,365.00 03/04/2025 Non-covered Recipient Entity
Best Skin Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226099002
Principal investigator 1 SANOFI US SERVICES INC. $585.00 03/04/2025 Non-covered Recipient Entity
Best Skin Research Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226099008
Principal investigator 1 SANOFI US SERVICES INC. $3,201.52 03/04/2025 Non-covered Recipient Entity
Best Skin Research Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226099013
Principal investigator 1 SANOFI US SERVICES INC. $4,321.11 03/04/2025 Non-covered Recipient Entity
Best Skin Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226099020
Principal investigator 1 Incyte Corporation $1,639.00 03/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507639
Principal investigator 1 Incyte Corporation $1,167.20 03/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507838
Principal investigator 1 Incyte Corporation $229.00 03/03/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527737
Principal investigator 1 Incyte Corporation $45.80 03/03/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240527743
Principal investigator 1 Incyte Corporation $231.40 03/03/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527756
Principal investigator 1 Incyte Corporation $77.75 03/03/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240527764
Principal investigator 1 Incyte Corporation $129.44 03/03/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527772
Principal investigator 1 Incyte Corporation $98.72 03/03/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527775
Principal investigator 1 Incyte Corporation $30.52 03/03/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527779
Principal investigator 1 Incyte Corporation $19.60 03/03/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527784
Principal investigator 1 Incyte Corporation $30.52 03/03/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527799
Principal investigator 1 Incyte Corporation $30.52 03/03/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527803
Principal investigator 1 Incyte Corporation $30.52 03/03/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527808
Principal investigator 1 SANOFI US SERVICES INC. $4,392.00 02/24/2025 Non-covered Recipient Entity
Best Skin Research Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226098944
Principal investigator 1 SANOFI US SERVICES INC. $4,269.00 02/24/2025 Non-covered Recipient Entity
Best Skin Research Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226098952
Principal investigator 1 SANOFI US SERVICES INC. $12,042.00 02/24/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226098957
Principal investigator 1 Incyte Corporation $1,329.10 02/21/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507652
Principal investigator 1 Incyte Corporation $1,460.00 02/21/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507672
Principal investigator 1 SANOFI US SERVICES INC. $17,752.00 02/10/2025 Non-covered Recipient Entity
Best Skin Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226098914
Principal investigator 1 SANOFI US SERVICES INC. $310.00 02/10/2025 Non-covered Recipient Entity
Best Skin Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226098921
Principal investigator 1 Eli Lilly and Company $226,921.00 02/05/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH LLC
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1187874851
Principal investigator 1 Incyte Corporation $155.50 02/05/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240527700
Principal investigator 1 Incyte Corporation $8.50 02/05/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240527721
Principal investigator 1 Incyte Corporation $52.48 02/05/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240527734
Principal investigator 1 Incyte Corporation $6.22 02/05/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240527748
Principal investigator 1 Incyte Corporation $155.50 02/05/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240527752
Principal investigator 1 Incyte Corporation $4.25 02/05/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240527760
Principal investigator 1 Incyte Corporation $93.30 02/05/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240527768
Principal investigator 1 Incyte Corporation $77.75 02/05/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240527788
Principal investigator 1 Incyte Corporation $77.75 02/05/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240527792
Principal investigator 1 Incyte Corporation $17.00 02/05/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240527796
Principal investigator 1 Incyte Corporation $93.30 02/05/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240527825
Principal investigator 1 SANOFI US SERVICES INC. $9,508.00 02/04/2025 Non-covered Recipient Entity
Best Skin Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226098891
Principal investigator 1 SANOFI US SERVICES INC. $2,420.00 02/04/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226098903
Principal investigator 1 Incyte Corporation $2,315.00 02/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507643
Principal investigator 1 Incyte Corporation $1,758.00 02/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507647
Principal investigator 1 Incyte Corporation $2,315.00 02/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507659
Principal investigator 1 Incyte Corporation $2,315.00 02/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507664
Principal investigator 1 Incyte Corporation $1,479.00 02/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507668
Principal investigator 1 Incyte Corporation $1,758.00 02/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507675
Principal investigator 1 Incyte Corporation $1,758.00 02/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507678
Principal investigator 1 Incyte Corporation $1,639.00 02/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507681
Principal investigator 1 Incyte Corporation $2,315.00 02/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507685
Principal investigator 1 Incyte Corporation $539.10 02/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507688
Principal investigator 1 Incyte Corporation $1,479.00 02/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507693
Principal investigator 1 Incyte Corporation $1,479.00 02/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507697
Principal investigator 1 Incyte Corporation $1,560.00 02/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507701
Principal investigator 1 Incyte Corporation $2,664.00 02/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507718
Principal investigator 1 Incyte Corporation $1,673.00 02/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507850
Principal investigator 1 Incyte Corporation $1,673.00 02/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507853
Principal investigator 1 Incyte Corporation $1,673.00 02/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507857
Principal investigator 1 Incyte Corporation $1,758.00 02/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507868
Principal investigator 1 Incyte Corporation $2,664.00 02/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507876
Principal investigator 1 Incyte Corporation $2,664.00 02/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507880
Principal investigator 1 Incyte Corporation $2,664.00 02/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507885
Principal investigator 1 Incyte Corporation $1,479.00 02/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507888
Principal investigator 1 Incyte Corporation $1,479.00 02/03/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240507892
Principal investigator 1 Amgen Inc. $19,874.55 01/27/2025 Non-covered Recipient Entity
BEST SKIN RESEARCH
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246639609
Principal investigator 1 SANOFI US SERVICES INC. $2,632.50 01/21/2025 Non-covered Recipient Entity
Best Skin Research Llc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226098861
Principal investigator 1 Incyte Corporation $120.00 01/02/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527692
Principal investigator 1 Incyte Corporation $84.48 01/02/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527696
Principal investigator 1 Incyte Corporation $173.43 01/02/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527704
Principal investigator 1 Incyte Corporation $17.64 01/02/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527709
Principal investigator 1 Incyte Corporation $99.12 01/02/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527713
Principal investigator 1 Incyte Corporation $1.31 01/02/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527717
Principal investigator 1 Incyte Corporation $371.70 01/02/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527725
Principal investigator 1 Incyte Corporation $22.89 01/02/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527730
Principal investigator 1 Incyte Corporation $22.89 01/02/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527812
Principal investigator 1 Incyte Corporation $22.89 01/02/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527817
Principal investigator 1 Incyte Corporation $22.89 01/02/2025 Non-covered Recipient Entity
DERMDOX DERMATOLOGY CENTERS, PC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240527820